RxDoctor Payments Data

Keren Stick, PA

Surgical · Round Rock, TXNPI 1679089866

Payments from drug & device makers

$3,749in general payments, 2019–2025

Across 118 payments — averaging $31.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Johnson & Johnson$455
  • AbbVie$362
  • Astellas Pharma US Inc$269
  • Sumitomo Pharma America, Inc.$247
  • Olympus America Inc.$192
  • plus $1K from 16 others

What the payments were for

  • Travel & lodging$1,05528%
  • Food & beverage$2,46166%
  • Education$2336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,749 in reported general payments places this provider in the 90th percentile of 804 surgical providers in Texas.

See all surgical providers in Texas

Medicare billing

Part B allowed, 2024
$200,615
Medicare patients
416
Services billed
6,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$179,461
GemtesaVibegron56$52,673
MyrbetriqMirabegron41$46,225
Mirabegron ErMirabegron22$16,722
Testosterone Cypionate109$5,614
Tamsulosin Hcl384$5,519
Alfuzosin Hcl ErAlfuzosin Hcl123$3,698
Estradiol53$2,587
Testosterone32$2,500
Dutasteride96$2,440
Potassium Citrate ErPotassium Citrate23$1,988
Solifenacin Succinate25$1,522
Finasteride92$1,474
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst85$1,213
Oxybutynin Chloride ErOxybutynin Chloride61$1,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$269$225,68654 claims
Sumitomo Pharma America, Inc.Gemtesa$247$52,67356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 surgical providers in Texas.

Other surgical in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →